ASCO 2019 | Bladder cancer: unmet need for novel therapies

Petros Grivas

Petros Grivas, MD, PhD, of the Seattle Cancer Care Alliance, Seattle, WA, discusses the PrE0807 (NCT03532451) trial that investigated the feasibility of neoadjuvant nivolumab (N)/lirilumab (L) in cisplatin-ineligible muscle-invasive bladder cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video